Results 1 to 10 of about 10,206 (212)

Pharmacometric‐Based Evaluation of Salmeterol and Its Metabolite α‐Hydroxysalmeterol in Plasma and Urine: Practical Implications for Doping Control [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Salmeterol is a commonly used β2‐agonist included on the List of Prohibited Substances and Methods published by the World Anti‐Doping Agency (WADA). We developed a population pharmacokinetic (popPK) model to describe the PK of salmeterol including its ...
Paul Thoueille, Anne Danion, Morten Hostrup, Michael Petrou, Koen Deventer, Thierry Buclin, François R. Girardin, Irene Mazzoni, Olivier Rabin, Monia Guidi   +9 more
doaj   +3 more sources

Onset of Bronchodilation and Finger Tremor Induced by Salmeterol and Salbutamol in Asthmatic Patients [PDF]

Canadian Respiratory Journal, 1998
Salmeterol is a beta-agonist with bronchodilator properties that last for at least 12 h after inhalation. However, the onset of action of salmeterol immediately after inhalation has not been sufficiently investigated.
Jan Lötvall, Helen Lunde, Nils Svedmyr
doaj   +2 more sources

Step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy

Journal of Asthma and Allergy, 2016
Kazuya Horiuchi, Keita Kasahara, Yusuke Kuroda, Haruna Morohoshi, Yosuke Hagiwara, Gen Ishii Respiratory Disease Center, Showa University Northern Yokohama Hospital, Yokohama-shi, Kanagawa-ken, Japan Purpose: A combination therapy with inhaled ...
Horiuchi K, Kasahara K, Kuroda Y, Morohoshi H, Hagiwara Y, Ishii G   +5 more
doaj   +3 more sources

Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study [PDF]

BMC Pulmonary Medicine, 2011
Background The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting β2-agonist (LABA) formoterol fumarate (formoterol) are being made available as a combination product (fluticasone/formoterol, flutiform®) in a single ...
McAulay Kirsten, Dymek Andrzej, Bodzenta-Lukaszyk Anna, Mansikka Heikki   +3 more
doaj   +2 more sources

Comparison of the effectiveness and safety of formoterol versus salmeterol in the treatment of patients with asthma: A systematic review and meta-analysis

Journal of Research in Medical Sciences, 2015
Background: Formoterol and salmeterol are two long-acting β2-agonists given by inhalation, with bronchodilating effects lasting for at least 12 h after a single administration. Formoterol has a faster onset of action compared with salmeterol.
Ashraf Velayati, Seyed Alireza Hosseini, Ali Akbari Sari, Farideh Mohtasham, Mostafa Ghanei, Mohsen Yaghoubi, Reza Majdzadeh   +6 more
doaj   +2 more sources

Salmeterol

Reactions Weekly, 2006
europepmc   +4 more sources

Molecular Dynamic Study of Mechanism Underlying Nature of Molecular Recognition and the Role of Crosslinker in the Synthesis of Salmeterol-Targeting Molecularly Imprinted Polymer for Analysis of Salmeterol Xinafoate in Biological Fluid

Molecules, 2022
The rational preparation of molecularly imprinted polymers (MIPs) in order to have selective extraction of salmeterol xinafoate (SLX) from serum was studied.
Shendi Suryana, Mutakin Mutakin, Yudi Rosandi, Aliya Nur Hasanah   +3 more
doaj   +1 more source

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids

BMC Infectious Diseases, 2020
Objectives To investigate the incidence of active tuberculosis (TB) among COPD patients using fluticasone/salmeterol or budesonide/formoterol, and to identify any differences between these two groups of patients.
Tsan-Ming Huang, Kuan-Chih Kuo, Ya-Hui Wang, Cheng-Yi Wang, Chih-Cheng Lai, Hao-Chien Wang, Likwang Chen, Chong-Jen Yu, On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE)   +8 more
doaj   +1 more source

Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease

Respiratory Research, 2010
Background The relationship between airway structural changes (remodeling) and airways hyperresponsiveness (AHR) is unclear. Asthma guidelines suggest treating persistent asthma with inhaled corticosteroids and long acting β-agonists (LABA).
Lundblad Lennart K, Haverkamp Hans C, Thompson-Figueroa John A, Sullivan Michael J, Riesenfeld Erik P, Bates Jason HT, Irvin Charles G   +6 more
doaj   +1 more source

Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials

ERJ Open Research, 2021
Inhaled corticosteroids have proven to be less effective in asthmatic patients who smoke; however, there is limited information on the efficacy of inhaled corticosteroid-containing regimens in COPD patients who continue smoking.
David M.G. Halpin, Claus F. Vogelmeier, Karen Mezzi, Pritam Gupta, Konstantinos Kostikas, Jadwiga A. Wedzicha   +5 more
doaj   +1 more source